Wilson2012 - tumor vaccine efficacy

  public model
Model Identifier
BIOMD0000000791
Short description
The paper describes a model of antitumor vaccine therapy. Created by COPASI 4.25 (Build 207) This model is described in the article: A Mathematical Model of the Enhancement of Tumor Vaccine Efficacy by Immunotherapy Shelby Wilson and Doron Levy Bull Math Biol. 2012 July ; 74(7) Abstract: TGF-β is an immunoregulatory protein that contributes to inadequate antitumor immune responses in cancer patients. Recent experimental data suggests that TGF-β inhibition alone, provides few clinical benefits, yet it can significantly amplify the anti-tumor immune response when combined with a tumor vaccine. We develop a mathematical model in order to gain insight into the cooperative interaction between anti-TGF-β and vaccine treatments. The mathematical model follows the dynamics of the tumor size, TGF-β concentration, activated cytotoxic effector cells, and regulatory T cells. Using numerical simulations and stability analysis, we study the following scenarios: a control case of no treatment, anti-TGF-β treatment, vaccine treatment, and combined anti-TGF-β vaccine treatments. We show that our model is capable of capturing the observed experimental results, and hence can be potentially used in designing future experiments involving this approach to immunotherapy. To cite BioModels Database, please use: BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models . To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication for more information.
Format
SBML (L3V1)
Related Publication
  • A mathematical model of the enhancement of tumor vaccine efficacy by immunotherapy.
  • Wilson S, Levy D
  • Bulletin of mathematical biology , 7/ 2012 , Volume 74 , Issue 7 , pages: 1485-1500 , PubMed ID: 22438084
  • Department of Mathematics and Center for Scientific Computation and Mathematical Modeling (CSCAMM), University of Maryland, College Park, MD 20742, USA. swilson@math.umd.edu
  • TGF-β is an immunoregulatory protein that contributes to inadequate antitumor immune responses in cancer patients. Recent experimental data suggests that TGF-β inhibition alone, provides few clinical benefits, yet it can significantly amplify the anti-tumor immune response when combined with a tumor vaccine. We develop a mathematical model in order to gain insight into the cooperative interaction between anti-TGF-β and vaccine treatments. The mathematical model follows the dynamics of the tumor size, TGF-β concentration, activated cytotoxic effector cells, and regulatory T cells. Using numerical simulations and stability analysis, we study the following scenarios: a control case of no treatment, anti-TGF-β treatment, vaccine treatment, and combined anti-TGF-β vaccine treatments. We show that our model is capable of capturing the observed experimental results, and hence can be potentially used in designing future experiments involving this approach to immunotherapy.
Contributors
Submitter of the first revision: Jinghao Men
Submitter of this revision: Krishna Kumar Tiwari
Modellers: Krishna Kumar Tiwari, Jinghao Men

Metadata information

isDescribedBy (1 statement)
PubMed 22438084

hasTaxon (1 statement)
Taxonomy Homo sapiens

hasProperty (2 statements)
Mathematical Modelling Ontology Ordinary differential equation model
Gene Ontology immune response to tumor cell

Curation status
Non-curated
Modelling approach(es)
ordinary differential equation model
Tags
Immuno-oncology

Connected external resources

SBGN view in Newt Editor

Name Description Size Actions

Model files
Wilson2012.xml SBML L3V1 representation of tumour vaccine model 69.27 KB Preview | Download

Additional files
Wilson2012.cps CPS file of the model in COPASI 85.93 KB Preview | Download
Wilson2012.sedml Auto-generated SEDML file 3.38 KB Preview | Download

  • Model originally submitted by : Jinghao Men
  • Submitted: Aug 12, 2019 4:32:18 PM
  • Last Modified: Mar 12, 2021 9:00:38 AM
Revisions
  • Version: 4 public model Download this version
    • Submitted on: Mar 12, 2021 9:00:38 AM
    • Submitted by: Krishna Kumar Tiwari
    • With comment: Updated event definition to resolve SBML L3V1 validation error.
  • Version: 3 public model Download this version
    • Submitted on: Aug 12, 2019 4:32:18 PM
    • Submitted by: Jinghao Men
    • With comment: Automatically added model identifier BIOMD0000000791

(*) You might be seeing discontinuous revisions as only public revisions are displayed here. Any private revisions unpublished model revision of this model will only be shown to the submitter and their collaborators.

Legends
: Variable used inside SBML models


Species
Species Initial Concentration/Amount
E

effector T cell 		100.0 mmol
R

regulatory T cell 		1.0 mmol
T

malignant cell 		3.0 mmol
V

effector T cell 		0.0 mmol
B

Transforming growth factor beta-1 		0.0 mmol
Reactions
Reactions Rate Parameters
E => tme*d1*E d1 = 1.0E-5 1/d
E => R tme*r*E r = 0.01 1/d
T => ; E, B tme*d0*E*T/(1+c1*B) c1 = 100.0 1; d0 = 1.0E-5 1/d
V => tme*d1*V d1 = 1.0E-5 1/d
T => ; V tme*d0*T*V d0 = 1.0E-5 1/d
=> E; T, B tme*f*E*T/(1+c3*T*B) f = 0.62 1/d; c3 = 300.0 1
B => tme*d*B d = 7.0E-4 1/d
R => tme*d1*R d1 = 1.0E-5 1/d
=> T tme*a0*T*(1-c0*T) a0 = 0.1946 1/d; c0 = 0.002710027100271 1
Curator's comment:
(added: 12 Aug 2019, 16:32:13, updated: 12 Aug 2019, 16:32:13)
Publication figure 4 reproduced similar to literature. Figure data is generated using COPASI 4.26 (build 213).